Phase II Trial of Systemic Continuous Fluorouracil and Subcutaneous Recombinant Interferon Alfa-2b for Treatment of Hepatocellular Carcinoma

First Page		Document Content
Date: 2003-01-14 17:33:38 Fibrolamellar hepatocellular carcinoma Liver cancer Renal cell carcinoma Cirrhosis Viral hepatitis Interferon AFP-L3 Des-gamma carboxyprothrombin Medicine Hepatology Hepatocellular carcinoma		Phase II Trial of Systemic Continuous Fluorouracil and Subcutaneous Recombinant Interferon Alfa-2b for Treatment of Hepatocellular Carcinoma Add to Reading List Source URL: jco.ascopubs.org Download Document from Source Website File Size: 80,46 KB Share Document on Facebook

	ABSTRACT Hepatocellular carcinoma (HCC), is increasingly common among those aging with HIV (HIV+). Compared with uninfected persons, HIV+ patients have a 4-fold increased risk of HCC. As HIV+ patients continue to age, HC DocID: 1v5Er - View Document
	Current Challenges in Systemic Therapy for Hepatocellular Carcinoma APASL STC, 23, Nov., 2013, Cebu Ann-Lii Cheng M.D., Ph.D. Professor and Chairman, Department of Oncology, DocID: 1uS8V - View Document
	HEPCAR_brochure_27june2017_Layout:00 Pagina 1 Mech anisms underl ying hepatocellular carcinoma pathogenesis and impact of co-morbidities THE PROBLEM DocID: 1uBCQ - View Document
	Ongoing Clinical Trials in Hepatocellular Carcinoma Pierce K.H Chow MD PhD DocID: 1tZOI - View Document
	Challenges in diagnosis of hepatocellular carcinoma Do Young Kim Department of Internal Medicine, Yonsei University College of Medicine DocID: 1tP8u - View Document